Leptin-dopamine interactions: unveiling the common link between type-2 diabetes and neuropsychiatric comorbidities.

IF 1.6 4区心理学 Q3 BEHAVIORAL SCIENCES

Behavioural Pharmacology Pub Date : 2025-08-01 Epub Date: 2025-07-02 DOI:10.1097/FBP.0000000000000820

Allyson Gill, Madison Gill, Rahul Mittal, Khemraj Hirani, Ajay Sharma

{"title":"Leptin-dopamine interactions: unveiling the common link between type-2 diabetes and neuropsychiatric comorbidities.","authors":"Allyson Gill, Madison Gill, Rahul Mittal, Khemraj Hirani, Ajay Sharma","doi":"10.1097/FBP.0000000000000820","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical evidence highlights the central nervous system as a key target in type-2 diabetes-related complications, yet the mechanisms underlying the increased prevalence of mood disorder issues, mainly depression, in patients with diabetes remain poorly understood. Leptin, an adiposity hormone known for its role in energy homeostasis, has been shown to improve insulin sensitivity and regulate blood glucose levels in diabetic populations. Beyond its metabolic effects, leptin also has the potential to mitigate psychiatric complications such as depression and anxiety. Notably, leptin receptors are predominantly expressed on dopamine (DA) neurons in the brain, hinting that leptin may orchestrate DA activity by serving as its endogenous modulator. This review examines the role of leptin as a potential common link between type-2 diabetes and mood disorders, particularly through its effects on DA function. This article proposes defective leptin signaling as a vital mechanism contributing to psychiatric complications and compromised DA functions in type-2 diabetes, highlighting leptin as a promising therapeutic target for addressing metabolic and psychiatric comorbidities.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":"217-225"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioural Pharmacology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1097/FBP.0000000000000820","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Clinical evidence highlights the central nervous system as a key target in type-2 diabetes-related complications, yet the mechanisms underlying the increased prevalence of mood disorder issues, mainly depression, in patients with diabetes remain poorly understood. Leptin, an adiposity hormone known for its role in energy homeostasis, has been shown to improve insulin sensitivity and regulate blood glucose levels in diabetic populations. Beyond its metabolic effects, leptin also has the potential to mitigate psychiatric complications such as depression and anxiety. Notably, leptin receptors are predominantly expressed on dopamine (DA) neurons in the brain, hinting that leptin may orchestrate DA activity by serving as its endogenous modulator. This review examines the role of leptin as a potential common link between type-2 diabetes and mood disorders, particularly through its effects on DA function. This article proposes defective leptin signaling as a vital mechanism contributing to psychiatric complications and compromised DA functions in type-2 diabetes, highlighting leptin as a promising therapeutic target for addressing metabolic and psychiatric comorbidities.

查看原文本刊更多论文

瘦素-多巴胺相互作用：揭示2型糖尿病和神经精神合并症之间的共同联系。

临床证据强调中枢神经系统是2型糖尿病相关并发症的关键靶点，但糖尿病患者情绪障碍问题（主要是抑郁症）患病率增加的机制仍知之甚少。瘦素是一种肥胖激素，以其在能量稳态中的作用而闻名，已被证明可以改善糖尿病人群的胰岛素敏感性并调节血糖水平。除了它的代谢作用，瘦素也有可能减轻精神并发症，如抑郁和焦虑。值得注意的是，瘦素受体主要在大脑中的多巴胺（DA）神经元上表达，这暗示瘦素可能通过作为其内源性调节剂来协调DA的活性。这篇综述探讨了瘦素作为2型糖尿病和情绪障碍之间潜在的共同联系的作用，特别是通过其对DA功能的影响。本文提出瘦素信号缺陷是导致2型糖尿病精神并发症和DA功能受损的重要机制，强调瘦素是解决代谢和精神合并症的有希望的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Behavioural Pharmacology 医学-行为科学

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Behavioural Pharmacology accepts original full and short research reports in diverse areas ranging from ethopharmacology to the pharmacology of schedule-controlled operant behaviour, provided that their primary focus is behavioural. Suitable topics include drug, chemical and hormonal effects on behaviour, the neurochemical mechanisms under-lying behaviour, and behavioural methods for the study of drug action. Both animal and human studies are welcome; however, studies reporting neurochemical data should have a predominantly behavioural focus, and human studies should not consist exclusively of clinical trials or case reports. Preference is given to studies that demonstrate and develop the potential of behavioural methods, and to papers reporting findings of direct relevance to clinical problems. Papers making a significant theoretical contribution are particularly welcome and, where possible and merited, space is made available for authors to explore fully the theoretical implications of their findings. Reviews of an area of the literature or at an appropriate stage in the development of an author’s own work are welcome. Commentaries in areas of current interest are also considered for publication, as are Reviews and Commentaries in areas outside behavioural pharmacology, but of importance and interest to behavioural pharmacologists. Behavioural Pharmacology publishes frequent Special Issues on current hot topics. The editors welcome correspondence about whether a paper in preparation might be suitable for inclusion in a Special Issue.